Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/S177 enrolled

Overview

This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

177

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

liraglutideDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects diagnosed with type 2 diabetes mellitus and treated with either diet or single oral drug therapy * Diet treated subjects: 7.5% \< HbA1c \< 10% * Single oral drug therapy subjects: 7.0% \< HbA1c \< 9.5% * Body Mass Index (BMI): max 40 kg/m\^2 Exclusion Criteria: * Subjects treated with thiazolidinediones or insulin * Subjects with any serious medical conditions

Locations (39)

Outcomes

Primary Outcomes

HbA1c

Time frame: after 14 weeks treatment

Secondary Outcomes

Body weight after 14 weeks.

Glycaemic control parameters (fasting plasma glucose, glucose profiles) after 14 weeks.

Safety and tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.